JP2021534129A5 - - Google Patents
Info
- Publication number
- JP2021534129A5 JP2021534129A5 JP2021506964A JP2021506964A JP2021534129A5 JP 2021534129 A5 JP2021534129 A5 JP 2021534129A5 JP 2021506964 A JP2021506964 A JP 2021506964A JP 2021506964 A JP2021506964 A JP 2021506964A JP 2021534129 A5 JP2021534129 A5 JP 2021534129A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- inhibitor
- combination according
- ret
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717480P | 2018-08-10 | 2018-08-10 | |
| US62/717,480 | 2018-08-10 | ||
| US201862735730P | 2018-09-24 | 2018-09-24 | |
| US62/735,730 | 2018-09-24 | ||
| PCT/US2019/045919 WO2020033838A2 (en) | 2018-08-10 | 2019-08-09 | Treatment of egfr-mutant cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534129A JP2021534129A (ja) | 2021-12-09 |
| JP2021534129A5 true JP2021534129A5 (enExample) | 2022-08-17 |
| JP7490635B2 JP7490635B2 (ja) | 2024-05-27 |
Family
ID=69415686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506964A Active JP7490635B2 (ja) | 2018-08-10 | 2019-08-09 | Ｅｇｆｒ変異がんの処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210308134A1 (enExample) |
| EP (1) | EP3833372A4 (enExample) |
| JP (1) | JP7490635B2 (enExample) |
| CN (1) | CN112703014A (enExample) |
| WO (1) | WO2020033838A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| PE20210096A1 (es) | 2018-04-03 | 2021-01-12 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret |
| EP4157230A1 (en) * | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Pralsetinib pharmaceutical compositions |
| EP4157829A1 (en) * | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| WO2022046867A1 (en) * | 2020-08-25 | 2022-03-03 | Loxo Oncology, Inc. | Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers |
| CN116867492A (zh) * | 2020-11-20 | 2023-10-10 | 赫尔森保健股份公司 | 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN113143931A (zh) * | 2021-04-16 | 2021-07-23 | 南方医科大学 | 甲磺酸奥西替尼在制备寻常型银屑病治疗药物中的应用 |
| CN116440136B (zh) * | 2023-04-17 | 2024-02-09 | 浙江大学智能创新药物研究院 | 甲磺酸阿美替尼在制备治疗乐伐替尼心脏毒性药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| WO2007087245A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Ret tyrosine kinase inhibition |
| WO2009003136A1 (en) | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
| CN103764676A (zh) | 2011-08-04 | 2014-04-30 | 日本国立癌症研究中心 | Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法 |
| BR112014004213A2 (pt) | 2011-08-23 | 2017-06-20 | Found Medicine Inc | novas moléculas de fusão kif5b-ret e usos das mesmas |
| CA2846496C (en) * | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ｒｅｔ融合体の検出法 |
| EP2878672A4 (en) | 2012-07-26 | 2016-02-17 | Nat Cancer Ct | FUSIONSGEN OF CEP55-GEN AND RET-GEN |
| CN105658814A (zh) | 2013-08-20 | 2016-06-08 | 日本国立癌症研究中心 | 在肺癌中检测出的新型融合基因 |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| MA43416A (fr) * | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| MX379513B (es) * | 2016-04-01 | 2025-03-11 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| US10934300B2 (en) | 2017-06-23 | 2021-03-02 | San Diego State University (Sdsu) Foundation | Atropisomerism for enhanced kinase inhibitor selectivity |
| CN109180677A (zh) | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
| WO2019008172A1 (en) | 2017-07-07 | 2019-01-10 | Nipd Genetics Public Company Limited | ENRICHED MULTIPLEXED PARALLEL ANALYSIS IN TARGET FOR TUMOR BIOMARKER EVALUATION |
| LT3728271T (lt) | 2017-12-19 | 2022-12-12 | Turning Point Therapeutics, Inc. | Makrocikliniai junginiai, skirti ligų gydymui |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
-
2019
- 2019-08-09 EP EP19847106.2A patent/EP3833372A4/en not_active Withdrawn
- 2019-08-09 CN CN201980060618.8A patent/CN112703014A/zh active Pending
- 2019-08-09 WO PCT/US2019/045919 patent/WO2020033838A2/en not_active Ceased
- 2019-08-09 US US17/267,149 patent/US20210308134A1/en not_active Abandoned
- 2019-08-09 JP JP2021506964A patent/JP7490635B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534129A5 (enExample) | ||
| Kim et al. | Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor | |
| JP2024133475A5 (enExample) | ||
| MA30967B1 (fr) | Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile. | |
| JP2011511071A5 (enExample) | ||
| JP2017533963A5 (enExample) | ||
| IL255312B (en) | Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist | |
| JP2024501471A5 (enExample) | ||
| JP2023530351A5 (enExample) | ||
| US20240229156A1 (en) | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles | |
| JP2013507415A5 (enExample) | ||
| JP2017529382A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2022533981A5 (enExample) | ||
| TW202332444A (zh) | 用於治療癌症之醫藥組成物 | |
| JP2022526159A5 (enExample) | ||
| WO2023114984A1 (en) | Tead inhibitors and uses thereof | |
| WO2023235716A2 (en) | Cancer treatment using topoisomerase i inhibitors and plk1 inhibitors | |
| JP2019524888A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| US20240350500A1 (en) | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | |
| US20230058305A1 (en) | Methods and compositions for treating myc-driven cancers | |
| JP2018522881A5 (enExample) | ||
| CN119604291A (zh) | Blu-945联合奥斯替尼治疗非小细胞肺癌 | |
| EP3236966B1 (en) | Combination of raf inhibitors and taxanes | |
| RU2695362C2 (ru) | Новое сочетание з-[(3-{ [4-(4-морфолинилметил)-1н-пиррол-2-ил]метилен} -2-оксо-2,3-дигидро-1н-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr |